ARCHIVES

Patient Satisfaction Was Crucial In ODAC Review Of Panretin

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

Board Oks Construction PA Fro Breast Cancer Research Facilities

July 9, 1993

Sharfstein To Leave FDA

January 7, 2011

Vitamin D Not Associated With Risk For Less Common Cancers, Study Finds

July 30, 2010

Bypass Budget Omits Needless Words: Faster Progress to Cost $421 Million More

March 29, 1996

Intarferon Results Promising, ACS Says, And commits Another $3.4 Million

February 22, 1980

Consortium Aims To Make Mice Whose Cancers Act Human.

January 7, 2000